1Y Close · As of Aug 26, 2026
Celltrion operates in the Pharmaceuticals sector.
Legal name: Celltrion, Inc.
In fiscal year 2025, Celltrion (068270) reported revenue of 4.16 trillion KRW, up 17.0% from 3.56 trillion KRW a year earlier.
Operating profit was 1.17 trillion KRW and net income was 1.03 trillion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 44.99 trillion KRW, with a P/B of 2.59.
These figures can be verified in the DART filing (receipt no. 20260316001415).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 4.2T | 1.2T | 1.0T |
| 2024 | 3.6T | 492.0B | 418.9B |
| 2023 | 2.2T | 651.5B | 539.7B |
Recent Filings
Rumor Clarification (Unconfirmed)
투자판단관련주요경영사항 (CTP51(키트루다 바이오시밀러) 한국 품)
Officer/Major Shareholder Ownership Report
Checks
1 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Treasury Stock: Treasury stock filings in the last 3 years: 4 acquisition(s), 2 cancellation(s).
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-25 | Rumor Clarification (Unconfirmed) |
| 2026-08-24 | 투자판단관련주요경영사항 (CTP51(키트루다 바이오시밀러) 한국 품) |
| 2026-08-21 | Officer/Major Shareholder Ownership Report |
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-14 | Payment and Dispute Resolution |